奥麦罗制药近日就其候选药物Narsoplimab用于治疗移植相关血栓性微血管病（TA-TMA）的欧洲市场授权申请，向公众披露了最新动态。此次更新标志着该药物在关键监管审批路径上迈入了新阶段。
奥麦罗制药近日就其候选药物Narsoplimab用于治疗移植相关血栓性微血管病（TA-TMA）的欧洲市场授权申请，向公众披露了最新动态。此次更新标志着该药物在关键监管审批路径上迈入了新阶段。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.